Symrise AG
Explore by topic
5-year stock timeline
2021
FY2021 delivered group sales of €3,826m with organic growth of 9.6%, EBITDA of €814m and net income of €375m. Symrise raised full-year targets during the year following strong H1 performance [13,16,26]. Residual operational disruption from a late-2020 cyberattack extended into early 2021 [22]. The stock moved through a clear uptrend as repeated beats and guidance raises produced a re-rating and established a higher base into 2022 [16,26]. Investors rewarded the combination of resilience, high margins and post-COVID recovery tailwinds [16,13].
2022
Symrise accelerated M&A activity: Schaffelaarbos (pet-protein) closed in January, followed by additional pet-nutrition and China-focused deals, then fine fragrance acquisitions (SFA Romani and Groupe Néroli) in April to strengthen the Scent & Care division [1,9,10,2,3,6]. FY2022 sales reached €4,618m, up 20.7% with organic growth of 11.4%, and EBITDA hit €922m before a €126m impairment on the Swedencare stake in Q4 [45,46,51]. Disposals of Velcorin and colours reduced reported sales by approximately €99m [5]. The stock rallied strongly through most of the year on exceptional organic growth and M&A momentum, though Q4 brought volatility when the Swedencare impairment and broader macro headwinds (rates and inflation) shifted sentiment [45,51].
2023
In February, Symrise took a strategic minority stake in biotech firm Synergio to expand natural antimicrobial and product-protection capabilities [27,29]. The company crossed 30% ownership in Swedencare in May and launched a mandatory tender offer at SEK 37.50 in June, which the Swedencare board recommended rejecting; Symrise later increased holdings through off-market purchases, reaching approximately 35.86% by year-end [35,36,38,34]. FY2023 group sales were approximately €4.73bn with organic growth of 7.9% and adjusted EBITDA of approximately €903m, though margins fell below pro-forma 2022 levels [53,34]. The stock experienced pronounced volatility around the June offer, then traded sideways as investors processed deal dynamics and slower EBITDA traction [35,41,53].
2024
FY2024 delivered group sales of approximately €4.99bn with improved profitability [24,18]. Symrise continued incremental Swedencare share purchases and post-offer adjustments throughout the year [43,44]. Margin and organic metrics stabilized, allowing investor perception to shift back toward "resilient compounder" as headline risk faded [18,24,44]. The stock recovered and broke out from the 2023 range as FY2024 beats and margin improvement took hold [18,24].
2025–H1 2026
FY2025 group sales reached approximately €4.93bn with organic growth of 2.8% and margin improvement; management reaffirmed medium-term targets for 2025–28 [54,19,23]. In early 2026, Symrise announced share-buyback actions and reported a Q1 beat with FY26 guidance of 2–4% organic growth, adjusted EBITDA margin of 21.5–22.5% and business free cash flow margin exceeding 14% [20,21,54]. The stock consolidated through 2025 on mixed top-line signals, then broke out in late 2025 and early 2026 following the buyback announcement, Q1 beat and constructive guidance. Current price as of July 7, 2026 stands at 90.94 [54,20,21].
Key risks and downside factors
Symrise operates in a concentrated global market for flavors, fragrances, and specialty ingredients. Competition comes from a handful of well-capitalized players—Givaudan, IFF, and DSM‑Firmenich dominate—alongside regional specialists like Takasago, Kerry, Sensient, and Robertet. These competitors span food, beverage, personal-care, and nutrition segments. The business faces persistent margin pressure from intense competition, volatility in input costs and supply chains (particularly for natural raw materials), regulatory and sustainability-driven reformulation requirements, and currency and commodity exposure across its global footprint.
- Larger global flavor and fragrance competitors—Givaudan, IFF, DSM-Firmenich—exert pricing pressure that can erode margins.
- Volatility in natural raw materials and aroma chemicals, combined with supply-chain disruptions, can elevate input costs and disrupt production schedules.
- Stricter regulation and sustainability requirements—encompassing REACH, food safety, labeling, and sustainable sourcing standards—may necessitate product reformulation, constrain ingredient availability, and elevate compliance expenses.
- Significant exposure to currency fluctuations, commodity inflation, and reliance on a small number of large food and personal-care customers—combined with sensitivity to emerging-market demand cycles—creates material risks to both revenue and profitability.
Competitive landscape
Symrise operates in a tightly consolidated global market for flavours, fragrances and active ingredients, where a handful of well-capitalized competitors—Givaudan, IFF, DSM-Firmenich among them—set the competitive tone. Regional players like Takasago, Sensient and T. Hasegawa hold their own niches. The structural pressures are real: pricing remains relentless, raw material costs for natural ingredients swing unpredictably, regulatory shifts force costly reformulations, and revenue leans heavily on a narrow customer base across geographies where currency fluctuations bite.
| Company | Ticker |
|---|---|
| Givaudan SA | GIVN.SIX |
| International Flavors & Fragrances Inc. | IFF.NYSE |
| DSM-Firmenich AG | DSFIR.AS |
| Sensient Technologies Corporation | SXT.NYSE |
Private competitors
- MANE SA
- Robertet Group
- Döhler GmbH
- Bell Flavors & Fragrances
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Symrise AG
Relative Performance vs Benchmarks
| Period | Symrise AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +20.01% | +18.30% | +18.60% |
| 3M | +27.71% | +22.54% | +17.45% |
| 6M | +31.98% | +32.86% | +23.68% |
| 1Y | +1.67% | -1.76% | -20.20% |
| 3Y | +1.12% | -59.35% | -75.86% |
| 5Y | -19.82% | -79.42% | -103.51% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 33.6 | 2.0 | 3.3 | 9.0 |
| 1Y ago | 20.3 | 2.0 | 3.4 | 14.2 |
| 3Y ago | 54.8 | 2.7 | 3.7 | 29.0 |
| 5Y ago | 33.5 | 3.1 | 6.7 | 21.1 |
Frequently Asked Questions
Where is the Symrise AG stock traded?
What does Symrise AG do?
What are the key metrics for SY1.XETRA?
How has Symrise AG's stock price performed?
How is SY1.XETRA valued?
Does SY1.XETRA pay dividends?
What are the key risks when investing in SY1.XETRA?
- Larger global flavor and fragrance competitors—Givaudan, IFF, DSM-Firmenich—exert pricing pressure that can erode margins.
- Volatility in natural raw materials and aroma chemicals, combined with supply-chain disruptions, can elevate input costs and disrupt production schedules.
- Stricter regulation and sustainability requirements—encompassing REACH, food safety, labeling, and sustainable sourcing standards—may necessitate product reformulation, constrain ingredient availability, and elevate compliance expenses.
- Significant exposure to currency fluctuations, commodity inflation, and reliance on a small number of large food and personal-care customers—combined with sensitivity to emerging-market demand cycles—creates material risks to both revenue and profitability.
Who are the main competitors of Symrise AG?
- Givaudan SA (GIVN.SIX)
- International Flavors & Fragrances Inc. (IFF.NYSE)
- DSM-Firmenich AG (DSFIR.AS)
- Sensient Technologies Corporation (SXT.NYSE)
When does Symrise AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.25 EUR | 1.65% | 1.25% |
| 2025 | 1.20 EUR | 1.14% | |
| 2024 | 1.10 EUR | 1.08% | |
| 2023 | 1.05 EUR | 0.97% | |
| 2022 | 1.02 EUR | 0.93% | |
| 2021 | 0.97 EUR | 0.89% | |
| 2020 | 0.95 EUR | 0.98% | |
| 2020 | 0.95 EUR | 1.02% | |
| 2019 | 0.90 EUR | 1.04% | |
| 2018 | 0.88 EUR | 1.23% | |
| 2017 | 0.85 EUR | 1.34% | |
| 2016 | 0.80 EUR | 1.40% | |
| 2015 | 0.75 EUR | 1.32% | |
| 2014 | 0.70 EUR | 1.84% | |
| 2013 | 0.65 EUR | 1.99% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 4.93B | 5.00B | 4.73B | 4.62B | 3.83B |
| Operating income (EBIT) | 609.30M | 717.80M | 559.36M | 503.98M | 558.96M |
| Net income | 249.30M | 478.20M | 340.47M | 280.01M | 374.92M |
| Free cash flow | 521.05M | 667.49M | 449.31M | 109.94M | 347.40M |
| Total assets | 8.11B | 8.32B | 7.85B | 7.78B | 6.64B |
| Equity | 3.72B | 3.98B | 3.63B | 3.55B | 3.19B |
| Net debt | 1.60B | 1.84B | 2.17B | 2.23B | 1.35B |
PWP Leeway UG (haftungsbeschränkt)
